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OBJECTIVE—Hyperglycemia induces reactive oxygen species
(ROS) and apoptosis in cardiomyocytes, which contributes to
diabetic cardiomyopathy. The present study was to investigate
the role of Rac1 in ROS production and cardiomyocyte apoptosis
during hyperglycemia.
RESEARCH DESIGN AND METHODS—Mice with cardio-
myocyte-speciﬁc Rac1 knockout (Rac1-ko) were generated. Hy-
perglycemia was induced in Rac1-ko mice and their wild-type
littermates by injection of streptozotocin (STZ). In cultured adult
rat cardiomyocytes, apoptosis was induced by high glucose.
RESULTS—The results showed a mouse model of STZ-induced
diabetes, 7 days of hyperglycemia-upregulated Rac1 and NADPH
oxidase activation, elevated ROS production, and induced apo-
ptosis in the heart. These effects of hyperglycemia were signiﬁ-
cantly decreased in Rac1-ko mice or wild-type mice treated with
apocynin. Interestingly, deﬁciency of Rac1 or apocynin treatment
signiﬁcantly reduced hyperglycemia-induced mitochondrial ROS
production in the heart. Deﬁciency of Rac1 also attenuated
myocardial dysfunction after 2 months of STZ injection. In
cultured cardiomyocytes, high glucose upregulated Rac1 and
NADPH oxidase activity and induced apoptotic cell death, which
were blocked by overexpression of a dominant negative mutant
of Rac1, knockdown of gp91
phox or p47
phox, or NADPH oxidase
inhibitor. In type 2 diabetic db/db mice, administration of Rac1
inhibitor, NSC23766, signiﬁcantly inhibited NADPH oxidase ac-
tivity and apoptosis and slightly improved myocardial function.
CONCLUSIONS—Rac1 is pivotal in hyperglycemia-induced ap-
optosis in cardiomyocytes. The role of Rac1 is mediated through
NADPH oxidase activation and associated with mitochondrial
ROS generation. Our study suggests that Rac1 may serve as a
potential therapeutic target for cardiac complications of
diabetes. Diabetes 58:2386–2395, 2009
D
iabetic cardiomyopathy has been deﬁned as
ventricular dysfunction that occurs in the ab-
sence of changes in blood pressure and coro-
nary artery disease (1,2). Cell death by
apoptosis is the predominant damage in diabetic cardio-
myopathy (3,4). Diabetes increases cardiac apoptosis in
animals and patients (3–7). Cardiomyocyte death causes a
loss of contractile tissue, which initiates a cardiac remod-
eling (8). Loss of cardiomyocytes and hypertrophy of the
remaining cells characterize the diabetic cardiomyopathy
(9,10). Thus, suppression of cardiomyocyte apoptosis re-
sults in a signiﬁcant prevention of the development of
diabetic cardiomyopathy (4). However, the underlying
mechanisms by which diabetes induce apoptosis remain
not fully understood.
All forms of diabetes are characterized by chronic
hyperglycemia. Hyperglycemia induces reactive oxygen
species (ROS) production in cardiomyocytes (6,11), which
plays a crucial role in cardiomyocyte apoptosis in diabetes
because the administration of antioxidant agents are able
to rescue hyperglycemia-induced cardiomyocytes (4,6).
The mechanisms activated by hyperglycemia, leading to
myocardial oxidative stress and apoptosis, are not com-
pletely clariﬁed.
Although multiple sources of ROS have been demon-
strated, NADPH oxidase is a critical determinant of the
redox state of the myocardium (12–15). Higher myocardial
NADPH oxidase activity has been detected in diabetes
(16,17); more importantly, NADPH oxidase activity is
markedly increased by high glucose levels (18). The
NADPH oxidase is a multicomponent enzyme complex
that consists of the membrane-bound cytochrome b558,
which contains gp91
phox and p22
phox, the cytosolic regula-
tory subunits p47
phox and p67
phox, and the small guanosine
triphosphate-binding protein Rac. An important step for
the assembly and function of this multicomponent NADPH
oxidase complex is the heterodimerization of gp91
phox
with p67
phox, which is mediated by Rac (19). Three iso-
forms of Rac (Rac1, Rac2, and Rac3) have been identiﬁed
(20), and Rac1 is the predominant isoform expressed in
cardiomyocytes (21). Thus, Rac1 activation may lead to
myocardial oxidative stress and apoptosis during hyper-
glycemia. A recent study showed that Rac1 contributes to
vascular injury in diabetes (22). However, no direct evi-
dence is available on Rac1 and NADPH oxidase activation
in cardiomyocyte apoptosis in diabetes.
In this study, we generated cardiomyocyte-speciﬁc Rac1
knockout (Rac1-ko) mice; analyzed the impact of Rac1 on
NADPH oxidase activation, mitochondrial ROS genera-
tion, and intracellular ROS production; and investigated
the role of Rac1 and NADPH oxidase activation in cardi-
omyocyte apoptosis during hyperglycemia.
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Animals and adult rat cardiomyocyte culture. This investigation conforms
with the guide for the care and use of laboratory animals published by the U.S.
National Institutes of Health (NIH Publication No. 85–23). All experimental
procedures were approved by the Animal Use Subcommittee at the University
of Western Ontario, Canada. Breeding pairs of C57BL/6 mice, mice bearing the
modiﬁed Rac1 gene containing loxP sites, and db/db mice were purchased
from the Jackson Laboratory. Transgenic mice with cardiomyocyte-speciﬁc
expression of Cre recombinase (Cre) under the control of -myosin heavy
chain (-MHC) were generously provided by Dr. Dale Evan Abel (University of
Utah, UT) (23). A breeding program for mice was implemented at our animal
care facilities.
Adult male rats (Sprague Dawley, 200 g body weight) were purchased from
Charles River Labs. Adult rat ventricle cardiomyocytes (ARVC) were isolated
and cultured as described (24).
Streptozotocin hyperglycemic mice. Adult male mice (2 months old) were
intraperitoneally injected with a single dose of streptozotocin (STZ) at 150
mg/kg body weight, dissolved in 10 mmol/l sodium citrate buffer (pH 4.5). On
day 3 after STZ treatment, whole blood was obtained from the mouse tail vein
and random glucose levels were measured using OneTouch Ultra 2 blood
glucose monitoring system (LifeScan, Mountainview, CA). Blood glucose
content of 20 mmol/l or greater was chosen as hyperglycemia for the present
study, whereas citrate buffer-treated mice were used as normoglycemia
(blood glucose 12 mmol/l).
Adenoviral infection of cultured ARVC. Cardiomyocytes were infected
with adenoviral vectors containing a dominant-negative mutant Rac1 (Ad-
RacN17, Vector Biolabs) or -gal (Ad-gal, Vector Biolabs) as a control at a
multiplicity of infection (MOI) of 100 PFU/cell. Adenovirus-mediated gene
transfer was implemented as we previously described (24).
Gp91
phox and p47
phox knockdown using small interfering RNA. To knock
down gp91
phox (Nox2) and p47
phox expression, a small interfering RNA
(siRNA) against rat Nox2 or p47
phox was obtained (Santa Cruz Biotechnology,
Santa Cruz, CA) and two different scramble siRNAs (Con1 and Con2) were
employed as control. Transfection was performed using TransMessenger
Transfection Reagent (Qiagen) according to manufacturer’s protocol as
described in our recent study (25).
Measurements of Rac1 activity. Activated Rac1 was determined by p21-
binding domain of p21-activated protein kinase 1 pull-down assay (Rac
Activation Assay Kit; Cell Biolabs) according to the manufacturer’s protocol.
NADPH oxidase activity assay. NADPH oxidase activity was assessed in
cell lysates by lucigenin-enhanced chemiluminescence (20 g of protein, 100
mol/l NADPH, 5 mol/l lucigenin) with a multilabel counter (Victor3 Wallac)
(25).
Intracellular ROS measurement. The formation of ROS was measured by
using the ROS-sensitive dye, 2,7-dichlorodihydro-ﬂuorescein diacetate (DCF-
DA, Invitrogen), as an indicator. The assay was performed on freshly dissected
heart tissues. Samples (50 g proteins) were incubated with 10 l of DCF-DA
(10 mol/l) for3ha t37°C. The ﬂuorescent product formed was quantiﬁed by
spectroﬂuorometer at the 485/525 nm. Changes in ﬂuorescence were ex-
pressed as arbitrary unit.
Active caspase-3 measurement. As described in detail previously (26),
caspase-3 activity in myocardial tissues and cardiomyocytes was measured by
using a caspase-3 ﬂuorescent assay kit (BIOMOL Research Laboratories).
In situ detection of apoptotic cells. To localize cells undergoing nuclear
DNA fragmentation in the myocardium, in situ terminal deoxynucleotidyl
transferase–mediated dUTP nick-end labeling (TUNEL) was performed using
an in situ apoptosis detection kit (Roche Biochemicals) as described previ-
ously (26).
Measurement of ROS in isolated mitochondria. Mitochondria were iso-
lated from the freshly harvested heart as previously described (27). Mitochon-
drial superoxide generation was measured by lucigenin-enhanced
chemiluminescence with a multilabel counter (Victor3 Wallac) using NADH
(250 mol/l) or succinate (2 mmol/l) (27). The formation of ROS in freshly
isolated mitochondria was measured on addition of pyruvate/malate by using
DCF-DA as an indicator (28).
Heart function assessment. Mouse hearts were isolated and perfused on a
Langendorff-system. Myocardial function was then determined as described in
our previous study (25). Maximal and minimal ﬁrst derivatives of force
(dF/dtmax and dF/dtmin) as the rate of contraction and relaxation were
analyzed by PowerLab Chart program (ADInstruments).
Statistical analysis. All data were given as means  SD. Differences
between two groups were compared by unpaired Student’s t test. For
multigroup comparisons, ANOVA followed by Student Newman-Keuls test
was performed. A value of P  0.05 was considered statistically signiﬁcant.
RESULTS
Upregulation of Rac1 activity by hyperglycemia. As
shown in Fig. 1, hyperglycemia signiﬁcantly increased
Rac1 activity in STZ-treated compared with citrate buffer–
treated hearts (Fig. 1A). In cultured ARVC exposed to
normal (5.5 mmol/l) or high glucose (33 mmol/l) for 1, 6,
and 24 h, Rac1 activity was signiﬁcantly upregulated by
high glucose compared with normal glucose (Fig. 1B).
Generation of cardiomyocyte-speciﬁc Rac1-ko mice.
Mice with cardiomyocyte-speciﬁc Rac1-ko were generated
by crossing the ﬂoxed Rac1 mice with mice overexpress-
ing Cre under the control of -MHC as we recently
described (29). PCR analysis identiﬁed mice carrying both
the homozygous loxP-Rac1-loxP gene and the -MHC-cre
transgene (Fig. 1C) as Rac1-ko mice. Deﬁciency of Rac1
decreased Rac1 mRNA expression in the heart (Fig. 1D).
Isolated cardiomyocytes of Rac1-ko mice exhibited a
signiﬁcant reduction of Rac1 protein expression as com-
pared with their wild-type littermates (Fig. 1E). These
animals grow normally into adulthood without any health
problems. Under normal condition, there were no differ-
ences in heart weight, body weight, ratio of heart weight
over body weight, heart rate (data not shown), and cardiac
contractility between Rac1-ko mice and their wild-type
littermates. Histological analysis showed no pathological
changes in Rac1-ko hearts. These observations suggest
FIG. 1. A and B: Effect of hyperglycemia on Rac1 activity in the heart
and cardiomyocytes. Hyperglycemia was induced in mice by STZ injec-
tion. Rac1 activity was determined in the heart. Hyperglycemia in-
creased Rac1 activity in wild-type mice (A). B: Cultured ARVC were
incubated with normal (5.5 mmol/l) or high glucose (33 mmol/l). Rac1
activity was measured at 1, 6, and 24 h after high glucose incubation.
Data are means  SD, n  3. *P < 0.05 versus control. C–F: Charac-
terization of mice with cardiomyocyte-speciﬁc Rac1-ko. C: Genotyping.
Tail DNA was used to determine the presence of ﬂoxed Rac1 gene and
the -MHC-Cre transgene by PCR. Mouse with both homozygous
loxP-Rac1-loxP and -MHC-cre transgene was identiﬁed as knockout
(lane 1). Lanes 2 and 3 show heterozygous and homozygous ﬂoxed
Rac1 gene, respectively. D: Expressions of Cre, Rac1, and GAPDH
mRNA were determined in the heart and lung by RT-PCR. Cre mRNA
was detected in Rac1-ko heart only as shown in left lane. The levels of
Rac1 mRNA were signiﬁcantly reduced in Rac1-ko heart. The low level
of Rac1 mRNA in Rac1-ko heart is most likely because of vascular Rac1.
In contrast, the Rac1 mRNA was not decreased in Rac1-ko lung. E:
Adult cardiomyocytes were isolated from Rac1-ko and wild-type mice.
Rac1 protein expression was determined by Western blot analysis. The
levels of Rac1 protein were signiﬁcantly decreased in Rac1-ko cardio-
myocytes. F: Rac1 activity was determined in Rac1-ko and wild-type
hearts after 7 days hyperglycemia. A representative Western blot from
three different hearts in each group shows downregulation of Rac1
activity in Rac1-ko hearts. WT, wild type; KO, knockout.
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affect basal myocardial function and morphology of the
heart, thus excluding the possible effects of Cre expres-
sion on the heart of Rac1-ko mice.
Role of Rac1 in NADPH oxidase activation and ROS
production in the hyperglycemic heart. Hyperglycemia
was induced in Rac1-ko mice and their corresponding
wild-type littermates including wild-type, ﬂoxed Rac1, and
Cre transgenic (Cre) mice by STZ. The levels of blood
glucose were monitored on day 0, 3, and 9 after STZ
injection. To eliminate possible confounding effects of
STZ, insulin was immediately given using a long-term
insulin preparation (Lantus Insulin glargine injection;
sanoﬁ-aventis Canada, Laval, Canada) at a dose of 5–15
units per mouse per day to maintain the blood glucose
levels between 5–12 mmol/l when hyperglycemia was
greater than 20 mmol/l on day 3 after STZ treatment in
wild-type mice. In sham- or STZ-injected mice, blood
glucose was not different between Rac1-ko mice and their
corresponding wild-type littermates including wild-type,
Rac1 ﬂoxed, and Cre mice (data not shown).
We ﬁrst determined Rac1 activity in the heart. There
was no difference of Rac1 activity in between Rac1-ko
corresponding wild-type littermates under basal or dia-
betic conditions. Therefore, Rac1 ﬂoxed mice were pre-
sented as littermate wild-type controls for Rac1-ko mice.
Rac1 activity was much lower in Rac1-ko compared with
wild-type hearts during hyperglycemia (Fig. 1F). We then
examined the membrane translocation of Rac1 and
p67
phox, as well as NADPH oxidase activation. As shown in
Fig. 2A, the protein levels of Rac1 and p67
phox in plasma
membranes were signiﬁcantly upregulated in hyperglyce-
mic compared with normoglycemic wild-type hearts,
which were correlated with the increases in NADPH
oxidase activity and ROS production in hyperglycemic
hearts (Fig. 2B and C). However, myocardial ROS produc-
tion was not increased in insulin supplemented mice (data
not shown). There were no changes in protein levels of
NADPH oxidase subunits, gp91
phox, p67
phox, and Rac1 in
hyperglycemic hearts (data not shown). Deletion of Rac1
decreased membrane Rac1 and p67
phox, NADPH oxidase
activation, and ROS production in the hyperglycemic heart
(Fig. 2A–C). Finally, we analyzed the effect of NADPH
oxidase activation on ROS production during hyperglyce-
mia. Adult wild-type mice were injected with STZ. Two
days later, apocynin (30 mg  kg
1  day
1) or vehicle was
given in drinking water for 7 days. The levels of blood
glucose were similar between apocynin- and vehicle-
treated mice on day 9 (data not shown). Administration of
apocynin blocked NADPH oxidase activity and ROS pro-
duction in hyperglycemic hearts (Fig. 2B and C). These
results demonstrate that Rac1 is required for NADPH
oxidase activation and ROS production during
hyperglycemia.
Decreased apoptosis in the hyperglycemic Rac1-ko
heart. Myocardial caspase-3 activity was not different
between Rac1-ko corresponding wild-type littermates in-
cluding wild-type, Rac1 ﬂoxed, and Cre mice under
either normal or diabetic conditions (data not shown).
Therefore, Rac1 ﬂoxed mice were chosen as littermate
wild-type controls for Rac1-ko mice in the following
experiments. Compared with citrate buffer–treated mice,
hyperglycemia signiﬁcantly increased myocardial
caspase-3 activity (Fig. 3A) and the number of TUNEL-
positive cardiomyocytes in STZ-treated wild-type mice
(Fig. 3B and C), whereas myocardial caspase-3 activity
was not increased in insulin-supplemented mice (data not
shown). These results exclude the direct possible effects
of STZ on myocardial apoptosis, which is in agreement
with a recent report (4). Deﬁciency of Rac1 decreased
caspase-3 activity and the number of TUNEL-positive cells
in the hyperglycemic heart (Fig. 3). Similarly, inhibition of
NDAPH oxidase by apocynin blocked caspase-3 activation
and reduced the number of TUNEL-positive cells in hyper-
glycemic hearts (Fig. 3D and E). These data demonstrate
that Rac1-NADPH oxidase activation induces apoptosis in
the hyperglycemic heart.
Role of Rac1 and NADPH oxidase in mitochondrial
ROS production. Mitochondria are known to constitu-
tively generate superoxide radicals as a by-product of
electron transport and are also important sources for
intracellular ROS production in hyperglycemia (30,31).
Inhibition of mitochondrial ROS production has been
shown to prevent the development of diabetic cardiomy-
opathy (32,33). We explored the impact of Rac1-NADPH
oxidase on mitochondria in producing ROS. Myocardial
A
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FIG. 2. Role of Rac1 in NADPH oxidase activation. Relocalization of
Rac1 and p67
phox to membrane (A), NADPH oxidase activity (B), and
ROS production (C) were determined in the hyperglycemic heart. The
protein levels of Rac1 (M-Rac1) and p67
phox (M-p67
phox) were de-
creased in the membrane fractions of Rac1-ko compared with wild-type
hyperglycemic hearts (A). Deﬁciency of Rac1 or apocynin (Apo) treat-
ment blocked the upregulation of NADPH oxidase activity (B) and
elevation of ROS production in hyperglycemic hearts (C). Data are
means  SD, n  4–6.*P < 0.05 versus sham or sham in wild type,
#P <
0.05 versus STZ in wild type or vehicle (Veh) in STZ, †P < 0.05 versus
ﬂoxed in STZ. M-Rac1 and M-p67
phox indicate membrane Rac1 and
p67
phox, respectively. WT, wild type; KO, knockout.
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littermates, and apocynin-treated mice on day 9 after STZ
treatment. We ﬁrst determined superoxide generation in
the isolated frozen-thawed mitochondria. In the normogly-
cemic hearts, addition of NADH but not NADPH slightly
increased superoxide production and there was no differ-
ence between Rac1-ko mice and wild-type littermates.
However, in the hyperglycemic hearts, mitochondria su-
peroxide production was signiﬁcantly increased (Fig. 4A).
Deﬁciency of Rac1 or apocynin administration decreased
mitochondrial superoxide production in the hyperglyce-
mic heart (Fig. 4A). Addition of succinate did not elicit
superoxide production in mitochondrial preparations
(data not shown). This suggests that mitochondrial com-
plex I and/or III but not complex II is involved in super-
oxide generation.
To further conﬁrm the role of Rac1 and NADPH oxidase
in mitochondrial ROS production, we analyzed the release
of ROS from mitochondria by using DCF-DA as an indica-
tor. Similarly, ROS production was increased in intact
mitochondria from the hyperglycemic compared with the
normoglycemic heart on addition of pyruvate/malate (5/5
mmol/l). Deletion of Rac1 or apocynin administration
blocked the increase of ROS production in mitochondria
from the hyperglycemic heart (Fig. 4B). Thus, these data
demonstrate that Rac1 and NADPH oxidase contribute to
mitochondrial ROS generation in the hyperglycemic heart.
Effects of Rac1 and NADPH oxidase inhibition on
apoptosis in cardiomyocytes. To determine whether
Rac1 activation directly contributes to apoptosis in cul-
tured ARVC exposed to high glucose, we used adenoviral
vector Ad-RacN17 expressing a dominant negative mutant
of Rac1, which speciﬁcally blocks Rac1 activation (22,34).
ARVC were infected with Ad-RacN17 or Ad-gal and then
incubated with normal (5.5 mmol/l) or high glucose (33
mmol/l) for 24 h. High glucose signiﬁcantly induced
NADPH oxidase activity in ARVC (Fig. 5A). In contrast,
equal amount of mannitol did not affect NADPH oxidase
activity (data not shown). Infection of Ad-RacN17 blocked
NADPH oxidase activity in high glucose–treated ARVC
(Fig. 5A). Similarly, high glucose signiﬁcantly increased
caspase-3 activity compared with normal glucose,
whereas, as an osmotic control, equal amount of mannitol
did not induce caspase-3 activity in ARVC (data not
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FIG. 3. Role of Rac1 in apoptosis in the heart. Hyperglycemia was
induced in Rac1-ko mice and wild-type littermates. A and D: Myocardial
caspase-3 activity was increased in hyperglycemic wild-type litter-
mates. Deﬁciency of Rac1 or apocynin treatment reduced caspase-3
activity in hyperglycemic hearts. B and E: Quantiﬁcation of TUNEL
staining–positive cardiomyocytes. Deﬁciency of Rac1 or apocynin de-
creased the number of TUNEL-staining cells. Data are means  SD, n 
4–6. *P < 0.05 versus sham or wild type and
#P < 0.05 versus STZ 
wild-type littermates (ﬂoxed Rac1) or vehicle (Veh) in STZ. C: Repre-
sentatives of TUNEL staining in cardiomyocytes (yellow-blown signal,
arrows showing nuclear localization) from hyperglycemic wild-type
hearts (a) and hyperglycemic Rac1-ko hearts (b). Magniﬁcation 40;
scale bar: 10 m. WT, wild type; KO, knockout. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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FIG. 4. Impact of Rac1 and NADPH oxidase on ROS generation in
isolated mitochondria. Myocardial mitochondria were isolated from
wild-type and Rac1-ko mice under normoglycemia or hyperglycemia
and were assayed for superoxide generation and ROS production (see
details in RESEARCH DESIGN AND METHODS). Hyperglycemia upregulated
both superoxide generation (A) and ROS production (B). Deﬁciency of
Rac1 or apocynin (Apo) treatment signiﬁcantly decreased superoxide
generation and ROS production in isolated mitochondria. Data are
means  SD, n  5–6. *P < 0.05 versus sham,
#P < 0.05 versus STZ 
Veh and †P < 0.05 versus STZ  wild-type littermates (ﬂoxed). KO,
knockout; Veh, vehicle.
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caspase-3 activity (Fig. 5B). In association with upregula-
tion of caspase-3 activity, high glucose increased the
percentage of annexin V positive cells, which was signiﬁ-
cantly reduced by infection of Ad-RacN17 (Fig. 5C and E).
The increased percentage of annexin V positive cells was
also signiﬁcantly reduced by a selective caspase-3 inhibi-
tor, AC-DEVD carbohydrate (up to 90% reduction). These
results suggest that Rac1 is important in high glucose–
induced apoptosis. Cardiomyocyte death was also mea-
sured by phosphatidylinositol nuclear staining. Compared
with normal glucose, high glucose increased the percent-
age of phosphatidylinositol positive cells, which was sig-
niﬁcantly decreased by Ad-RacN17 (Fig. 5D and F).
Although phosphatidylinositol is a viability exclusion dye
and does not enter cells with intact membrane, in the late
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integrity as the cell dies (35). As such, the population of
phosphatidylinositol-positive cells is a mixture of necrotic
and apoptotic cells.
To examine if NADPH oxidase activation mediated
apoptosis, we ﬁrst incubated ARVC with normal or high
glucose in the presence of apocynin (100 mol/l), NAC (2
mmol/l), or vehicle. Twenty-four hours later, coincubation
with apocynin or NAC inhibited caspase-3 activity and
decreased the percentage of annexin-V positive and phos-
phatidylinositol-positive cells in high glucose–induced
ARVC (Fig. 6A–C). To clarify the contribution of gp91
phox-
NADPH oxidase, we transfected ARVC with gp91
phox-
speciﬁc siRNA and then incubated these cells with normal
or high glucose for another 24 h. Two different scramble
siRNAs (Con1 and Con2) were used as controls. Transfec-
tion with gp91
phox siRNA signiﬁcantly decreased gp91
phox
protein compared with either Con1 or Con2 siRNA in
ARVC (Fig. 6D). To conﬁrm the speciﬁc knockdown by
gp91
phox siRNA, we also measured Nox4 expression be-
cause our recent study has shown that cardiomyocytes
express both Nox2 and Nox4 under physiological condi-
tions (25). Gp91
phox siRNA did not alter Nox4 expression
in ARVC (data not shown). In response to high glucose,
gp91
phox siRNA blocked caspase-3 activation and reduced
annexin V–staining positive cells in ARVC (Fig. 6E and F),
compared with either Con1 or Con2 scramble siRNA.
These results demonstrate that gp91
phox-NADPH oxidase
activation induces apoptosis in high glucose–stimulated
ARVC. The role of NADPH oxidase in high glucose–
induced apoptosis was further demonstrated by using
p47
phox siRNA. Transfection of p47
phox siRNA blocked
NADPH oxidase activation in high glucose–stimulated
ARVC (data not shown). Similarly, caspase-3 activation
and annexin V–staining positive cells were signiﬁcantly
decreased in p47
phox siRNA–transfected ARVC (Fig. 6G
and H).
Contribution of Rac1 to myocardial dysfunction in
STZ-induced type 1 diabetic mice. To investigate the
functional signiﬁcance of Rac1, we assessed myocardial
function in Rac1-ko and wild-type mice after 8 weeks of
STZ injection. Although there was no change in heart rate,
rate of contraction/relaxation was signiﬁcantly reduced in
diabetic wild-type mice compared with sham animals (Fig.
7). Lack of Rac1 restored the rate of contraction and
relaxation without affecting heart rate in diabetic Rac1-ko
mice (Fig. 7). These results demonstrate that Rac1 con-
tributes to myocardial dysfunction in diabetic mice.
Role of Rac1 in cardiac apoptosis in db/db mice. To
further demonstrate the role of Rac1 in cardiac apoptosis
in diabetes, we used type 2 diabetic model of db/db mice.
A highly selective Rac1 inhibitor NSC23766 (36) was given
to db/db mice starting at age of 12 weeks (2.5 mg  kg
1
day
1 i.p.) for 2 weeks. Rac1 activity, NADPH oxidase
activity, caspase-3 activity, and TUNEL-positive cells were
signiﬁcantly increased in the heart of db/db mice com-
pared with wild-type mice (Fig. 8A–D). Administration of
NSC23766 inhibited NADPH oxidase activation, blocked
caspase-3 activity, and reduced TUNEL-positive cells in
db/db mice (Fig. 8B–D), whereas blood glucose levels were
similar between NSC23766 and vehicle-treated db/db mice
(20–28 mmol/l). Finally, myocardial dysfunction in db/db
mice was slightly but not signiﬁcantly (P  0.1418 and
0.0648 for the rate of contraction and relaxation, respec-
tively) attenuated by NSC23766 treatment (Fig. 8E and F).
DISCUSSION
The present study generated cardiomyocyte-speciﬁc
Rac1-ko mice and investigated the role of Rac1 in ROS
production and apoptosis in the hyperglycemic hearts. We
demonstrated for the ﬁrst time that Rac1, through
gp91
phox-NADPH oxidase activation and ROS production,
induces apoptosis in both hyperglycemic hearts and high
glucose–stimulated cardiomyocytes. Rac1 also plays a role
in cardiac apoptosis in type 2 diabetic db/db mice. Further-
more, Rac1 and NADPH oxidase activation is associated
with mitochondrial ROS production in the hyperglycemic
hearts. Finally, Rac1 contributes to myocardial dysfunc-
tion in STZ-induced type 1 diabetes. Thus, Rac1/NADPH
oxidase/mitochondrion axis is important in ROS produc-
tion and cardiomyocyte apoptosis in hyperglycemia,
which may contribute to the development of diabetic
cardiomyopathy.
Accumulating evidence suggests that hyperglycemia in-
duces ROS (6,11) and overproduction of ROS is associated
with apoptosis in the diabetic heart (4,6). However, the
pathophysiologically relevant source of increased myocar-
dial ROS production in diabetes remains to be further
characterized. Recent studies have demonstrated that
myocardial NADPH oxidase activity is increased in diabe-
tes (16,17). Hyperglycemia has been shown to activate
NADPH oxidase in cardiomyocytes (18). These studies
suggest the pathophysiological relevance of NADPH oxi-
dase activation for cardiomyocyte apoptosis in hypergly-
cemia. An important step for the assembly of active
NADPH oxidase is the interaction between cytosolic sub-
units (p67
phox, p47
phox, and Rac1) and membrane subunits
(gp91
phox and p22
phox) (19). Rac1 is required to anchor
cytosolic p67
phox to the membrane for the assembly of
active NADPH oxidase, leading to superoxide generation
(21). In the present study, deﬁciency of Rac1 inhibited the
relocalization of NADPH oxidase subunits to membrane
and diminished NADPH oxidase activation and ROS pro-
duction in the hyperglycemic heart. Either Rac1 deletion
or inhibition of NADPH oxidase prevented myocardial
apoptosis in hyperglycemia. These ﬁndings suggest that
Rac1 contributes to apoptosis through NADPH oxidase
activation in the hyperglycemic heart. To characterize
whether the role of Rac1 in apoptosis could be reproduced
by high glucose levels, we extended our analyses to
cardiomyocytes. Direct exposure of RAVC to high glucose,
through Rac1, promoted NADPH oxidase activation and
induced apoptosis. Selective inhibition of Rac1, knock-
down of gp91
phox or p47
phox, or scavenging ROS prevented
apoptosis in high glucose–stimulated ARVC. These data
support the notion that Rac1 is critical for gp91
phox-
NADPH oxidase activation, which is the major source of
ROS production responsible for apoptosis in cardiomyo-
cytes under hyperglycemic conditions. Rac1 was also
reported to induce NADPH oxidase activation and ROS
production in angiotensin-II stimulated cardiomyocytes
(21). Thus, the results reported herein also suggest that
Rac1 may be a universal mechanism for NADPH oxidase
activation in the heart under various stresses, which may
have potential therapeutic implications.
Mitochondrion is another important source of ROS
production contributing to apoptosis (37,38). Increased
mitochondrial ROS generation has been shown in diabetic
hearts (4,33,39). However, relatively few studies have
directly measured mitochondrial ROS production in the
isolated mitochondria from diabetic hearts, and the cross
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FIG. 6. Roles of gp91
phox-NADPH oxidase in cardiomyocyte apoptosis. Cultured cardiomyocytes were incubated with normal or high glucose in the
presence of apocynin (Apo), NAC, or vehicle for 24 h. Caspase-3 activity and cell death were determined. Caspase-3 activity (A), the percentages
of annexin V (B) and phosphatidylinositol staining–positive cells (C) were signiﬁcantly inhibited by incubation with apocynin or NAC in high
glucose–stimulated cardiomyocytes. D–F: Cardiomyocytes were transfected with gp91
phox (Nox2) siRNA, p47
phox siRNA, or scramble siRNAs
(Con1 or Con2) as control. Twenty-four hours later, the cells were incubated with normal or high glucose for another 24 h. D: Representative
Western blot for Nox2 protein in Nox2 siRNA and Con1- or Con2-siRNA–transfected cardiomyocytes. E and G: Caspase-3 activity. F and H: The
percentages of annexin V. Data are means  SD from at least three different cell cultures. *P < 0.05 versus Veh in normal glucose or Con1 in
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fully elucidated. In the present study, we measured ROS
production directly from the isolated mitochondria and
analyzed the role of Rac1-NADPH oxidase in mitochon-
drial ROS production. In agreement with a recent report of
Boudina et al. (39), our data showed that ROS production
was increased in the isolated mitochondria from the
hyperglycemic hearts. The increased mitochondrial ROS
was achieved by using mitochondrial complex I sub-
strates, NADH or pyruvate/malate, but not succinate, a
complex II substrate; this is different from the result of
Boudina et al. (39), which demonstrated that mitochon-
drial ROS is induced on addition of succinate in the
isolated mitochondria from the diabetic heart. The cause
of this discrepancy is unknown but may result from
different diabetic models used. Interestingly, cardiomyo-
cyte-speciﬁc deletion of Rac1 or inhibition of NADPH
oxidase signiﬁcantly attenuated ROS production in iso-
lated mitochondria from the hyperglycemic heart, suggest-
ing that Rac1 and NADPH oxidase activation functions
upstream of mitochondrion in generating mitochondrial
ROS in cardiomyocytes exposed to hyperglycemia. This
ﬁnding is supported by a recent observation demonstrat-
ing that NADPH oxidase–derived superoxide anion (O2
-)
directly activates the mitoKATP channels, presumably
through a direct action on the sulfhydryl groups of this
channel, or reacts with nitric oxide to form peroxynitrite
in vascular endothelial cells in response to angiotensin-II
(40). Both the increase in K
 inﬂux through opening of the
mitoKATP channels and the peroxynitrite formation can
damage respiratory complexes, leading to mitochondrial
ROS production (41). Alternatively, one-electron transfer
and/or rapid dismutation of superoxide result in substan-
tial H2O2 generation. H2O2 is a quantitatively important
signaling species (42), which may mediate mitochondrial
ROS production. Indeed, direct addition of H2O2 to iso-
lated mitochondria signiﬁcantly increased superoxide gen-
eration (E.S. and T.P., unpublished data). Whether these
mechanisms operate in the diabetic heart is currently
unknown but merits further investigations. On the other
hand, H2O2 converted from superoxide in the mitochon-
dria can diffuse to the cytoplasm, where it could activate
NADPH oxidase producing ROS. Recent studies have
suggested that mitochondrial ROS activate PI3K and PKC.
Activation of PI3K in turn promotes Rac1 and subsequent
NADPH oxidase activation (43,44), and PKC induces
NADPH oxidase activation via p47
phox phosphorylation
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inhibits NADPH oxidase expression and activation (46).
Thus, a mutual functional relationship between NADPH
oxidase and mitochondria in a feed-forward fashion may
favor sustaining ROS production, which promotes apopto-
sis in the hyperglycemic heart. Future studies will be
required to investigate this functional cross talk between
Rac1-NADPH oxidase and mitochondrion.
The present study also found that deﬁciency of Rac1
attenuated myocardial dysfunction in diabetic mice, sug-
gesting a pathophysiological signiﬁcance of Rac1 activa-
tion in diabetic hearts. This protection may result from
inhibition of cardiomyocyte apoptosis by Rac1 blockade.
Rac1-mediated ROS has been shown to induce cardiac
hypertrophy in response to angiotensin-II stimulation (21).
A recent study also indicated that Rac1 may be associated
with cardiac inﬂammatory responses in hyperglycemia
(47). Both cardiac hypertrophy and inﬂammation are im-
portant in the development of cardiac complications of
diabetes. Thus, it is possible that Rac1 via NADPH oxidase
activation and ROS production contributes to the diabetic
cardiac hypertrophy, inﬂammatory responses, mitochon-
drial dysfunction, in addition to apoptosis, leading to
myocardial dysfunction in diabetes (Fig. 9), which requires
further investigations. However, Rac1 may also play a role
in cardiac hypertrophy in diabetes through NADPH
oxidase–independent pathways (48).
It is worthwhile to mention that Rac1 activity was
decreased by about 40% in the whole heart of Rac1-ko
mice compared with their wild-type littermates. The exact
deletion of Rac1 in cardiomyocytes from Rac1-ko mice is
currently unknown. A recent study showed that the Cre-
loxP system could achieve 	70% deletion of Rac1 in
cardiomyocytes in transgenic mice (21). Thus, the deletion
of Rac1 in cardiomyocytes from our Rac1-ko mice is
estimated to be around 40–70%, which may lead to some
limitations of the interpretation of results from the present
study. For example, it is unclear whether further down-
regulation of Rac1 provides a better protection in diabetic
hearts. However, complete deletion of Rac1 may have
adverse effects since recent studies have suggested that
Rac1 is also required for cardiovascular development and
physiological functions (49,50).
Inconclusion,Rac1playsacriticalroleinhyperglycemia-
induced apoptosis in cardiomyocytes through NADPH
oxidase activation and ROS production, leading to myo-
cardial dysfunction in diabetes. Furthermore, Rac1 and
NADPH oxidase activation contributes to mitochondrial
ROS production in the hyperglycemic heart. Given exces-
sive ROS and cardiac apoptosis signiﬁcantly contributes to
diabetic cardiomyopathy (1–3,6,32,33,51), these ﬁndings
suggest that myocardial Rac1 may serve as a potential
target for the treatment of cardiac complications in
diabetes.
ACKNOWLEDGMENTS
This study was supported by grants from the Heart &
Stroke Foundation of Ontario (NA 5940) and the Canadian
Institutes of Health Research (MOP 93657) awarded to
T.P. T.P. is a recipient of a New Investigator Award from
Heart & Stroke Foundation of Canada and Rick Gallop
Award for research excellence from Heart & Stroke Foun-
dation of Ontario (2006).
No potential conﬂicts of interest relevant to this article
were reported.
REFERENCES
1. Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: the search
for a unifying hypothesis. Circ Res 2006;98:596–605
2. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007;
115:3213–3223
3. Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, Nadal-
Ginard B, Anversa P. Myocardial cell death in human diabetes. Circ Res
2000;87:1123–1132
4. Cai L, Wang Y, Zhou G, Chen T, Song Y, Li X, Kang YJ. Attenuation by
metallothionein of early cardiac cell death via suppression of mitochon-
drial oxidative stress results in a prevention of diabetic cardiomyopathy.
J Am Coll Cardiol 2006;48:1688–1697
5. Fiordaliso F, Leri A, Cesselli D, Limana F, Safai B, Nadal-Ginard B, Anversa
P, Kajstura J. Hyperglycemia activates p53 and p53-regulated genes leading
to myocyte cell death. Diabetes 2001;50:2363–2375
6. Fiordaliso F, Bianchi R, Staszewsky L, Cuccovillo I, Doni M, Laragione T,
Salio M, Savino C, Melucci S, Santangelo F, Scanziani E, Masson S, Ghezzi
P, Latini R. Antioxidant treatment attenuates hyperglycemia-induced car-
diomyocyte death in rats. J Mol Cell Cardiol 2004;37:959–968
7. Cai L, Li W, Wang G, Guo L, Jiang Y, Kang YJ. Hyperglycemia-induced
apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated
caspase-3 activation pathway. Diabetes 2002;51:1938–1948
8. Kajstura J, Fiordaliso F, Andreoli AM, Li B, Chimenti S, Medow MS, Limana
F, Nadal-Ginard B, Leri A, Anversa P. IGF-1 overexpression inhibits the
development of diabetic cardiomyopathy and angiotensin II-mediated
oxidative stress. Diabetes 2001;50:1414–1424
9. Adeghate E. Molecular and cellular basis of the aetiology and management
of diabetic cardiomyopathy: a short review. Mol Cell Biochem 2004;261:
187–191
10. Cai L, Kang YJ. Cell death and diabetic cardiomyopathy. Cardiovasc
Toxicol 2003;3:219–228
11. Modesti A, Bertolozzi I, Gamberi T, Marchetta M, Lumachi C, Coppo M,
Moroni F, Toscano T, Lucchese G, Gensini GF, Modesti PA. Hyperglycemia
activates JAK2 signaling pathway in human failing myocytes via angioten-
sin II-mediated oxidative stress. Diabetes 2005;54:394–401
12. Isabelle M, Vergeade A, Moritz F, Dautreaux B, Henry JP, Lallemand F,
Richard V, Mulder P, Thuillez C, Monteil C. NADPH oxidase inhibition
prevents cocaine-induced up-regulation of xanthine oxidoreductase and
cardiac dysfunction. J Mol Cell Cardiol 2007;42:326–332
13. Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel JL, Hasenfuss G,
Shah AM. Increased myocardial NADPH oxidase activity in human heart
failure. J Am Coll Cardiol 2003;41:2164–2171
14. Li JM, Gall NP, Grieve DJ, Chen M, Shah AM. Activation of NADPH oxidase
Hyperglycemia/ Diabetes
Rac1
NADPH oxidase Mitochondrion
ROS
Apoptosis Fibrosis Hypertrophy Inflammatory 
response
Myocardial dysfunction
Energy
depletion
FIG. 9. Proposed mechanisms for Rac1-induced cardiac damage in
diabetes. Hyperglycemia/diabetes activates Rac1 and subsequent
NADPH oxidase, producing ROS, which induce mitochondrial ROS
production. ROS production induces cardiac apoptosis, hypertrophy,
ﬁbrosis, and inﬂammatory response, leading to myocardial dysfunc-
tion. ROS damages mitochondrial function resulting in apoptosis and
energy depletion, which contributes to myocardial dysfunction. Rac1
activation may also induce cardiac hypertrophy through NADPH oxi-
dase–independent mechanisms. ROS indicates reactive oxygen species.
ROLE OF Rac1 IN APOPTOSIS
2394 DIABETES, VOL. 58, OCTOBER 2009 diabetes.diabetesjournals.orgduring progression of cardiac hypertrophy to failure. Hypertension 2002;
40:477–484
15. Xiao L, Pimentel DR, Wang J, Singh K, Colucci WS, Sawyer DB. Role of
reactive oxygen species and NAD(P)H oxidase in (1)-adrenoceptor
signaling in adult rat cardiac myocytes. Am J Physiol Cell Physiol
2002;282:C926–C934
16. Wold LE, Ceylan-Isik AF, Fang CX, Yang X, Li SY, Sreejayan N, Privratsky
JR, Ren J. Metallothionein alleviates cardiac dysfunction in streptozotocin-
induced diabetes: role of Ca
2 cycling proteins, NADPH oxidase, poly-
(ADP-Ribose) polymerase and myosin heavy chain isozyme. Free Radic
Biol Med 2006;40:1419–1429
17. Wendt MC, Daiber A, Kleschyov AL, Mulsch A, Sydow K, Schulz E, Chen K,
Keaney JF, Jr, Lassegue B, Walter U, Griendling KK, Munzel T. Differential
effects of diabetes on the expression of the gp91
phox homologues nox1 and
nox4. Free Radic Biol Med 2005;39:381–391
18. Privratsky JR, Wold LE, Sowers JR, Quinn MT, Ren J. AT1 blockade
prevents glucose-induced cardiac dysfunction in ventricular myocytes:
role of the AT1 receptor and NADPH oxidase. Hypertension 2003;42:206–
212
19. Babior BM, Lambeth JD, Nauseef W. The neutrophil NADPH oxidase. Arch
Biochem Biophys 2002;397:342–344
20. Haataja L, Groffen J, Heisterkamp N. Characterization of RAC3, a novel
member of the 
 family. J Biol Chem 1997;272:20384–20388
21. Satoh M, Ogita H, Takeshita K, Mukai Y, Kwiatkowski DJ, Liao JK.
Requirement of Rac1 in the development of cardiac hypertrophy. Proc Natl
Acad SciUSA2006;103:7432–7437
22. Vecchione C, Aretini A, Marino G, Bettarini U, Poulet R, Maffei A, Sbroggio
M, Pastore L, Gentile MT, Notte A, Iorio L, Hirsch E, Tarone G, Lembo G.
Selective Rac-1 inhibition protects from diabetes-induced vascular injury.
Circ Res 2006;98:218–225
23. Abel ED, Kaulbach HC, Tian R, Hopkins JC, Duffy J, Doetschman T,
Minnemann T, Boers ME, Hadro E, Oberste-Berghaus C, Quist W, Lowell
BB, Ingwall JS, Kahn BB. Cardiac hypertrophy with preserved contractile
function after selective deletion of GLUT4 from the heart. J Clin Invest
1999;104:1703–1714
24. Li Y, Arnold JM, Pampillo M, Babwah AV, Peng T. Taurine prevents
cardiomyocyte death by inhibiting NADPH oxidase-mediated calpain acti-
vation. Free Radic Biol Med 2009;46:51–61
25. Peng T, Lu X, Feng Q. Pivotal role of gp91phox-containing NADH oxidase
in lipopolysaccharide-induced tumor necrosis factor- expression and
myocardial depression. Circulation 2005;111:1637–1644
26. Feng Q, Song W, Lu X, Hamilton JA, Lei M, Peng T, Yee SP. Development
of heart failure and congenital septal defects in mice lacking endothelial
nitric oxide synthase. Circulation 2002;106:873–879
27. Chen Q, Vazquez EJ, Moghaddas S, Hoppel CL, Lesnefsky EJ. Production
of reactive oxygen species by mitochondria: central role of complex III.
J Biol Chem 2003;278:36027–36031
28. Mattiasson G. Analysis of mitochondrial generation and release of reactive
oxygen species. Cytometry A 2004;62:89–96
29. Rui T, Feng Q, Lei M, Peng T, Zhang J, Xu M, Abel ED, Xenocostas A,
Kvietys PR. Erythropoietin prevents the acute myocardial inﬂammatory
response induced by ischemia/reperfusion via induction of AP-1. Cardio-
vasc Res 2005;65:719–727
30. Yu T, Robotham JL, Yoon Y. Increased production of reactive oxygen
species in hyperglycemic conditions requires dynamic change of mito-
chondrial morphology. Proc Natl Acad SciUSA2006;103:2653–2658
31. Lin Y, Berg AH, Iyengar P, Lam TK, Giacca A, Combs TP, Rajala MW, Du
X, Rollman B, Li W, Hawkins M, Barzilai N, Rhodes CJ, Fantus IG,
Brownlee M, Scherer PE. The hyperglycemia-induced inﬂammatory re-
sponse in adipocytes: the role of reactive oxygen species. J Biol Chem
2005;280:4617–4626
32. Ye G, Metreveli NS, Donthi RV, Xia S, Xu M, Carlson EC, Epstein PN.
Catalase protects cardiomyocyte function in models of type 1 and type 2
diabetes. Diabetes 2004;53:1336–1343
33. Shen X, Zheng S, Metreveli NS, Epstein PN. Protection of cardiac mito-
chondria by overexpression of MnSOD reduces diabetic cardiomyopathy.
Diabetes 2006;55:798–805
34. Ito M, Adachi T, Pimentel DR, Ido Y, Colucci WS. Statins inhibit -adren-
ergic receptor-stimulated apoptosis in adult rat ventricular myocytes via a
Rac1-dependent mechanism. Circulation 2004;110:412–418
35. Trump BF, Berezesky IK, Chang SH, Phelps PC. The pathways of cell
death: oncosis, apoptosis, and necrosis. Toxicol Pathol 1997;25:82–88
36. Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y. Rational design and
characterization of a Rac GTPase-speciﬁc small molecule inhibitor. Proc
Natl Acad SciUSA2004;101:7618–7623
37. Zhao K, Zhao GM, Wu D, Soong Y, Birk AV, Schiller PW, Szeto HH.
Cell-permeable peptide antioxidants targeted to inner mitochondrial mem-
brane inhibit mitochondrial swelling, oxidative cell death, and reperfusion
injury. J Biol Chem 2004;279:34682–34690
38. Nagy N, Malik G, Tosaki A, Ho YS, Maulik N, Das DK. Overexpression of
glutaredoxin-2 reduces myocardial cell death by preventing both apoptosis
and necrosis. J Mol Cell Cardiol 2008;44:252–260
39. Boudina S, Sena S, Theobald H, Sheng X, Wright JJ, Hu XX, Aziz S, Johnson
JI, Bugger H, Zaha VG, Abel ED. Mitochondrial energetics in the heart in
obesity-related diabetes: direct evidence for increased uncoupled respira-
tion and activation of uncoupling proteins. Diabetes 2007;56:2457–2466
40. Doughan AK, Harrison DG, Dikalov SI. Molecular mechanisms of angio-
tensin II-mediated mitochondrial dysfunction: linking mitochondrial oxi-
dative damage and vascular endothelial dysfunction. Circ Res 2008;102:
488–496
41. Panov AV, Lund S, Greenamyre JT. Ca
2-induced permeability transition in
human lymphoblastoid cell mitochondria from normal and Huntington’s
disease individuals. Mol Cell Biochem 2005;269:143–152
42. Jones DP. Radical-free biology of oxidative stress. Am J Physiol Cell
Physiol 2008;295:C849–C868
43. Lee SB, Bae IH, Bae YS, Um HD. Link between mitochondria and NADPH
oxidase 1 isozyme for the sustained production of reactive oxygen species
and cell death. J Biol Chem 2006;281:36228–36235
44. Desouki MM, Kulawiec M, Bansal S, Das GM, Singh KK. Cross talk between
mitochondria and superoxide generating NADPH oxidase in breast and
ovarian tumors. Cancer Biol Ther 2005;4:1367–1373
45. Rathore R, Zheng YM, Niu CF, Liu QH, Korde A, Ho YS, Wang YX. Hypoxia
activates NADPH oxidase to increase [ROS]i and [Ca
2]i through the
mitochondrial ROS-PKCepsilon signaling axis in pulmonary artery smooth
muscle cells. Free Radic Biol Med 2008;45:1223–1231
46. Guo Z, Xia Z, Jiang J, McNeill JH. Downregulation of NADPH oxidase,
antioxidant enzymes, and inﬂammatory markers in the heart of streptozo-
tocin-induced diabetic rats by N-acetyl-L-cysteine. Am J Physiol Heart Circ
Physiol 2007;292:H1728–H1736
47. Van Linthout S, Riad A, Dhayat N, Spillmann F, Du J, Dhayat S, Wester-
mann D, Hilﬁker-Kleiner D, Noutsias M, Laufs U, Schultheiss HP, Tschope
C. Anti-inﬂammatory effects of atorvastatin improve left ventricular func-
tion in experimental diabetic cardiomyopathy. Diabetologia 2007;50:1977–
1986
48. Lezoualc’h F, Metrich M, Hmitou I, Duquesnes N, Morel E. Small GTP-
binding proteins and their regulators in cardiac hypertrophy. J Mol Cell
Cardiol 2008;44:623–632
49. Tan W, Palmby TR, Gavard J, Amornphimoltham P, Zheng Y, Gutkind JS.
An essential role for Rac1 in endothelial cell function and vascular
development. Faseb J 2008;22:1829–1838
50. Sawada N, Salomone S, Kim HH, Kwiatkowski DJ, Liao JK. Regulation of
endothelial nitric oxide synthase and postnatal angiogenesis by Rac1. Circ
Res 2008;103:360–368
51. Cai L. Suppression of nitrative damage by metallothionein in diabetic heart
contributes to the prevention of cardiomyopathy. Free Radic Biol Med
2006;41:851–861
E. SHEN AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 58, OCTOBER 2009 2395